Natera, Inc. (NTRA) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 27 analysts7.2% Above Target
NTRA trades 7.2% above Wall Street's consensus target of $261.00.
Current Price$281.27
Average Target$261.00
Target
Current
Low$220.00
Median$265.00
High$290.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth-1.0%
(Declining)
Analyst Spread26.8%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes NTRA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 27 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
NTRA Price Target Analysis
Updated July 8, 2026As of July 8, 2026, Natera, Inc. (NTRA) has a Wall Street consensus price target of $261.00, based on estimates from 27 covering analysts. With the stock currently trading at $281.27, this represents a potential downside of -7.2%. The company has a market capitalization of $40.28B.
Analyst price targets range from a low of $220.00 to a high of $290.00, representing a 27% spread in expectations. The median target of $265.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 24 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NTRA trades at a trailing P/E of -185.0x. Analysts expect EPS to grow -1.0% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+15.5%
Industry Consensus
Avg Forward P/E
107.4x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
 ILMNIllumina, Inc. | $29.1B | $191.76 | $156.27 | -18.5% | Buy | 36.6x | 50 |
 CGENCompugen Ltd. | $226M | $2.39 | $4.50 | +88.3% | Buy | — | 14 |
 MYRGMYR Group Inc. | $6.5B | $419.08 | $412.67 | -1.5% | Hold | 36.7x | 21 |
 PACBPacific Biosciences of California, Inc. | $485M | $1.56 | $1.00 | -35.9% | Buy | — | 18 |
 PRMEPrime Medicine, Inc. | $721M | $3.99 | $7.00 | +75.4% | Buy | — | 9 |
 CDNACareDx, Inc | $1.5B | $28.31 | $27.00 | -4.6% | Buy | 30.3x | 13 |
 TMOThermo Fisher Scientific Inc. | $192.0B | $516.62 | $592.45 | +14.7% | Buy | 20.8x | 42 |
 DHRDanaher Corporation | $137.4B | $194.19 | $230.89 | +18.9% | Buy | 23.0x | 43 |
 AAgilent Technologies, Inc. | $37.0B | $131.14 | $154.75 | +18.0% | Buy | 21.7x | 41 |
NTRA — Frequently Asked Questions
Quick answers to the most common questions about buying NTRA stock.
What is the NTRA stock price target for 2026?
Wall Street's consensus price target for NTRA is $261, -7.2% from its current price of $281.27. The below-market target from 27 analysts suggests limited near-term appreciation.
Is NTRA a buy, sell, or hold?
NTRA has a consensus rating of "Buy" based on 27 Wall Street analysts. The rating breakdown is predominantly bullish, with 24 Buy/Strong Buy ratings. The consensus 12-month price target of $261 implies -7.2% downside from current levels.
Is NTRA stock overvalued or undervalued?
NTRA's current price is $281.27 with a consensus target of $261 (-7.2% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can NTRA stock go?
The most bullish Wall Street analyst has a price target of $290 for NTRA, while the most conservative target is $220. The consensus of $261 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover NTRA stock?
NTRA is heavily covered by Wall Street, with 27 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 24 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the NTRA stock forecast?
The 12-month NTRA stock forecast based on 27 Wall Street analysts shows a consensus price target of $261, with estimates ranging from $220 (bear case) to $290 (bull case). The median consensus rating is "Buy".
Should I buy NTRA stock?
Analysts are cautious on NTRA, with 0 Sell ratings and a price target of $261 (-7.2% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do NTRA price targets vary so much?
NTRA analyst price targets range from $220 to $290, a 27% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $261 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare